⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2024

Table S3 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER⁺ Breast Cancer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Hallmark pathways enriched in ER+ PDX tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef20 https://doi.org/10.1158/1535-7163.27142207

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S5 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer2024
2Figure S6 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer2024
3Figure S1 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer2024
4Table S2 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer2024
5Table S6 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer2024